Pangaea Oncology

Pangaea Oncology is a private, revenue-generating company positioned as a precision oncology service provider and diagnostic developer in Southern Europe. Its core activities include a clinical reference laboratory offering comprehensive molecular diagnostics and companion diagnostics, and a preclinical services division (Pangaea Lab) specializing in biomarker discovery, organoid technology, and in-vitro testing. The company leverages its integrated clinical and R&D capabilities to serve both healthcare providers and pharmaceutical partners, with a strategic vision centered on data exploitation and AI to advance personalized cancer treatment.

Advanced molecular diagnostics platform specializing in comprehensive genetic alteration detection, liquid biopsy technology, massive sequencing, and AI/data analytics for predictive modeling. Includes organoid technology for in-vitro preclinical testing.

Pangaea Oncology competes in the fragmented molecular diagnostics and clinical lab services market. Key competitors include large global players like Foundation Medicine (Roche) and Guardant Health in liquid biopsy, as well as numerous regional and hospital-affiliated laboratories in Spain and Europe. Its differentiation lies in its integrated clinical-R&D model, focus on Southern Europe, and specialized expertise in translational oncology.